MD Anderson

Neoadjuvant Immunotherapy With Relatlimab And Nivolumab Is Safe And Effective In Stage Iii Melanoma

Study provides further evidence for pre-surgery immune checkpoint inhibitors in operable skin cancer  Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in […]

MD Anderson receives CPRIT funding to expand access to cervical cancer screening and treatment in Texas 

Kathleen Schmeler, M.D.

The University of Texas MD Anderson Cancer Center today was awarded $2.5 million in continued funding from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the expansion of cervical cancer prevention services to rural and medically underserved populations. While cervical […]

Md Anderson And BostonGene Announce Strategic Alliance To Advance Personalized Cancer Diagnostics And Treatments

MD Anderson

The University of Texas MD Anderson Cancer Center and BostonGene Corporation today announced a strategic alliance to advance the development and clinical integration of multiplatform biomarker signatures. The alliance brings together BostonGene’s innovative computational platform and CLIA-certified and CAP-accredited high complexity molecular laboratory with […]

MD Anderson Research Highlights: ESMO 2021 Special Edition

MD Anderson

Key presentations to focus on novel cell therapies, antibody-drug conjugates and neoadjuvant immunotherapy The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and clinical cancer research from MD Anderson experts. […]

MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting

Rodabe Amaria, M.D., Jennifer Litton, M.D., Funda Meric-Bernstam, M.D., Shannon Westin, M.D.

Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. The results of these studies, which will be presented at the […]

Metabolic Inhibitor Iacs-6274 Shows Early Antitumor Effects In Underserved Patients With Advanced Cancers

Timothy A. Yap, M.B.B.S, Ph.D.

Drug developed by MD Anderson’s Therapeutics Discovery division is well-tolerated with effective glutaminase inhibition in Phase I trial The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division, appears to be well-tolerated […]